Linked Life Data

12548512

Source:http://linkedlifedata.com/resource/pubmed/id/12548512

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12548512rdf:typepubmed:Citationlld:pubmed
pubmed-article:12548512lifeskim:mentionsumls-concept:C0019163lld:lifeskim
pubmed-article:12548512lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:12548512lifeskim:mentionsumls-concept:C0023911lld:lifeskim
pubmed-article:12548512lifeskim:mentionsumls-concept:C0209738lld:lifeskim
pubmed-article:12548512lifeskim:mentionsumls-concept:C0199176lld:lifeskim
pubmed-article:12548512lifeskim:mentionsumls-concept:C0034897lld:lifeskim
pubmed-article:12548512lifeskim:mentionsumls-concept:C0062525lld:lifeskim
pubmed-article:12548512lifeskim:mentionsumls-concept:C0348016lld:lifeskim
pubmed-article:12548512lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:12548512lifeskim:mentionsumls-concept:C0442117lld:lifeskim
pubmed-article:12548512lifeskim:mentionsumls-concept:C0439836lld:lifeskim
pubmed-article:12548512lifeskim:mentionsumls-concept:C0443252lld:lifeskim
pubmed-article:12548512pubmed:issue2lld:pubmed
pubmed-article:12548512pubmed:dateCreated2003-1-27lld:pubmed
pubmed-article:12548512pubmed:abstractTextRecurrent hepatitis B infection after liver transplantation was previously frequent and associated with significant allograft failure and mortality. Recurrence rates of hepatitis B were improved with the use of passive immunoprophylaxis with hepatitis B immune globulin, and later, lamivudine monotherapy. Combination prophylaxis with intravenous hepatitis B immune globulin and lamivudine substantially decreased rates of hepatitis B recurrence, but intravenous administration of hepatitis B immune globulin was expensive and associated with significant adverse effects. In the current study, 59 patients receiving primary liver transplantation for chronic hepatitis B infection were prospectively followed up after converting from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine. All patients tolerated intramuscular hepatitis B immune globulin well. At a median follow-up of 511 days after conversion to intramuscular hepatitis B immune globulin, 58 of 59 patients (98.3%) were hepatitis B surface antigen-negative. Twenty-one patients (35.6%) required a median of one supplemental intravenous hepatitis B immune globulin infusion to maintain therapeutic antibody levels. Economic analysis showed an average cost-effectiveness ratio for combination intramuscular hepatitis B immune globulin plus lamivudine of $52,600 per recurrence prevented, which was far below the cost of lamivudine monotherapy and of intravenous hepatitis B immune globulin alone or in combination with lamivudine. These results suggest that intramuscular administration of hepatitis B immune globulin in combination with lamivudine offers a safe, effective, and cost-effective approach to preventing hepatitis B recurrence after orthotopic liver transplantation.lld:pubmed
pubmed-article:12548512pubmed:languageenglld:pubmed
pubmed-article:12548512pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12548512pubmed:citationSubsetIMlld:pubmed
pubmed-article:12548512pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12548512pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12548512pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12548512pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12548512pubmed:statusMEDLINElld:pubmed
pubmed-article:12548512pubmed:monthFeblld:pubmed
pubmed-article:12548512pubmed:issn1527-6465lld:pubmed
pubmed-article:12548512pubmed:authorpubmed-author:BusuttilRonal...lld:pubmed
pubmed-article:12548512pubmed:authorpubmed-author:MartinPaulPlld:pubmed
pubmed-article:12548512pubmed:authorpubmed-author:SaabSammySlld:pubmed
pubmed-article:12548512pubmed:authorpubmed-author:GhobrialRafik...lld:pubmed
pubmed-article:12548512pubmed:authorpubmed-author:GoldsteinLeon...lld:pubmed
pubmed-article:12548512pubmed:authorpubmed-author:HoltCurtisClld:pubmed
pubmed-article:12548512pubmed:authorpubmed-author:FarmerDouglas...lld:pubmed
pubmed-article:12548512pubmed:authorpubmed-author:DurazoFrancis...lld:pubmed
pubmed-article:12548512pubmed:authorpubmed-author:HanSteven-Huy...lld:pubmed
pubmed-article:12548512pubmed:authorpubmed-author:EdelsteinMarc...lld:pubmed
pubmed-article:12548512pubmed:authorpubmed-author:HuRenaRlld:pubmed
pubmed-article:12548512pubmed:authorpubmed-author:KunderGreggGlld:pubmed
pubmed-article:12548512pubmed:issnTypePrintlld:pubmed
pubmed-article:12548512pubmed:volume9lld:pubmed
pubmed-article:12548512pubmed:ownerNLMlld:pubmed
pubmed-article:12548512pubmed:authorsCompleteYlld:pubmed
pubmed-article:12548512pubmed:pagination182-7lld:pubmed
pubmed-article:12548512pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:12548512pubmed:meshHeadingpubmed-meshheading:12548512...lld:pubmed
pubmed-article:12548512pubmed:meshHeadingpubmed-meshheading:12548512...lld:pubmed
pubmed-article:12548512pubmed:meshHeadingpubmed-meshheading:12548512...lld:pubmed
pubmed-article:12548512pubmed:meshHeadingpubmed-meshheading:12548512...lld:pubmed
pubmed-article:12548512pubmed:meshHeadingpubmed-meshheading:12548512...lld:pubmed
pubmed-article:12548512pubmed:meshHeadingpubmed-meshheading:12548512...lld:pubmed
pubmed-article:12548512pubmed:meshHeadingpubmed-meshheading:12548512...lld:pubmed
pubmed-article:12548512pubmed:meshHeadingpubmed-meshheading:12548512...lld:pubmed
pubmed-article:12548512pubmed:meshHeadingpubmed-meshheading:12548512...lld:pubmed
pubmed-article:12548512pubmed:meshHeadingpubmed-meshheading:12548512...lld:pubmed
pubmed-article:12548512pubmed:meshHeadingpubmed-meshheading:12548512...lld:pubmed
pubmed-article:12548512pubmed:meshHeadingpubmed-meshheading:12548512...lld:pubmed
pubmed-article:12548512pubmed:meshHeadingpubmed-meshheading:12548512...lld:pubmed
pubmed-article:12548512pubmed:meshHeadingpubmed-meshheading:12548512...lld:pubmed
pubmed-article:12548512pubmed:meshHeadingpubmed-meshheading:12548512...lld:pubmed
pubmed-article:12548512pubmed:meshHeadingpubmed-meshheading:12548512...lld:pubmed
pubmed-article:12548512pubmed:meshHeadingpubmed-meshheading:12548512...lld:pubmed
pubmed-article:12548512pubmed:meshHeadingpubmed-meshheading:12548512...lld:pubmed
pubmed-article:12548512pubmed:meshHeadingpubmed-meshheading:12548512...lld:pubmed
pubmed-article:12548512pubmed:meshHeadingpubmed-meshheading:12548512...lld:pubmed
pubmed-article:12548512pubmed:meshHeadingpubmed-meshheading:12548512...lld:pubmed
pubmed-article:12548512pubmed:meshHeadingpubmed-meshheading:12548512...lld:pubmed
pubmed-article:12548512pubmed:year2003lld:pubmed
pubmed-article:12548512pubmed:articleTitleConversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation.lld:pubmed
pubmed-article:12548512pubmed:affiliationDivision of Digestive Diseases, UCLA School of Medicine, Los Angeles, CA, USA. shbhan@ucla.edulld:pubmed
pubmed-article:12548512pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12548512lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12548512lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12548512lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12548512lld:pubmed